It is the generic version of AstraZeneca’s Xylocaine ointment
Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administration for Lidocaine ointment USP, five per cent , the generic version of Xylocaine Ointment, five per cent of AstraZeneca.
According to IMS Health sales data for the 12 month period ending July 2016, the Xylocaine ointment, five per cent market achieved annual sales of approximately $373.0 million.
Glenmark’s current portfolio consists of 109 products authorised for distribution in the US marketplace and 62 ANDA’s pending approval with the US FDA.
- Advertisement -
Comments are closed.